LXEO - Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. Common Stock Logo

LXEO - Lexeo Therapeutics, Inc. Common Stock

https://www.lexeotx.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company is headquartered in New York, New York.

52W High
$11.45
52W Low
$1.45
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
N/A
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-6.02
EV/Revenue (<3 favorable)
416.34
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
1.96
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
0.53%
Institutions (25–75% balanced)
89.31%
Shares Outstanding
54,001,000
Float
29,378,400
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
-73,681,000
EPS (TTM)
-3.21
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.75%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
0.2032
Previous
0.2047
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025